Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old.

The South Korean Ministry of Food and Drug Safety have approved a local trial to evaluate nafamostat’s effectiveness in COVID-19 patients.

Scott Morrison, the Australian Prime Minister, has called for an investigation into the origins of the COVID-19 coronavirus, as Australia becomes one of China’s most vocal critics of its response to the pandemic.

The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19.

Nearly half of US states will have their ‘stay-at-home’ orders expire this week, paving the way for much of the US to relax its lockdowns.

A “landmark” partnership has been struck between AstraZeneca and the University of Oxford in the ongoing battle against COVID-19, with the former agreeing to aid in the development and large-scale manufacture of the latter’s potential recombinant adenovirus vaccine for the prevention of novel coronavirus infection.

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe on four separate patents, and has delayed them from launching until 2031.

The search for a COVID-19 treatment has ramped up this week, with two new studies detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with coronavirus, while researchers in America have been studying famotidine, the active ingredient in Pepcid, as a potential drug to help alleviate symptoms of the virus.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its recommendation for the approval of Kalydeco for the treatment of children and adolescents with cystic fibrosis in a new indication, Vertex has revealed.

US Secretary of State Mike Pompeo claimed that there is evidence the COVID-19 coronavirus was created in a lab, despite US intelligence officials stating it probably occurred naturally.

British scientists are testing an experimental drug to help some of society’s most vulnerable fight off the COVID-19 coronavirus.

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus.

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC), the most common skin cancer in the world, with around two million new cases diagnosed each year in the US alone.

The NHS’s coronavirus contract tracing app has been published to Apple and Google’s app stores with council staff and healthcare workers being invited to download it on the Isle of Wight today.

A new online reporting site has been launched by the Medicines and Healthcare products Regulatory Agency’s (MHRA) to track potential side-effects arising from the use of any therapies used to treat COVID-19, in a bid to build a knowledge base around safe treatment of the pandemic disease.

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular death and hospitalisation in adult patients with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

South Korea says that remdesivir, traditionally used in treating Ebola, may not be effective enough in treating COVID-19 patients.

Britain has become the first European nation to pass 30,000 deaths from the coronavirus, putting it only behind the US as the worst hit country in the world in terms of fatalities.

A recent report from the Office of National Statistics (ONS) has shown that black people in Britain are four times more likely to die from the COVID-19 coronavirus than white Britons.

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in patients who have residual invasive disease in the breast or lymph nodes after receiving neoadjuvant treatment including a HER2-targeted agent.

Aims to track the progress of the infection across the UK

New crop of data suggests drug can speed recovery from COVID-19

Ramps up capacity for testing across the country

Move comes after drug showed preliminary efficacy in clinical trial in late April

Eight new medicines recommended for approval

Click to view a price quote on ELAN.

Click to view a price quote on TLRY.

India continues to be on the 'Priority Watch List' of the US Trade Representative (USTR) for lack of…

A new collaboration targeting rare heart diseases has been formed between California’s BioMarin Pharmaceutical…

UK-based Mallinckrodt Pharmaceuticals has ended a trial of INOmax (nitric oxide) gas early due to positive…

The European medicines regulator has OK’d a label update for AstraZeneca’s Lokelma (sodium zirconium…

A new collaboration between Shanghai’s Junshi Biosciences and Eli Lilly will seek to develop novel…

Specialty chemicals company Evonik has kicked off a major expansion project at two German facilities,…

The COVID-19 pandemic did not stop China from launching its national blockchain-based service network…

Positive top-line data for a pivotal, single-arm, open-label trial of PD-1 inhibitor Libtayo (cemiplimab)…

Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter…

Shares of US biotech Akebia Therapeutics were up more than 35% at $11.72 by early afternoon today, after…

Almost a year after the original announcement, the US Federal Trade Commission (FTC) has accepted the…

California’s Gilead Sciences has outlined a plan to ramp up production of newly USA-approved COVID-19…

Following a couple of active M&A years, USA-based Alexion Pharmaceuticals has now reached a definitive…

Danish drugmaker Acesion Pharma, which is focused on novel treatments for atrial fibrillation (AF), has…

Pandemic-based stockpiling among people with diabetes helped lift revenues beyond analysts’ expectations…

US drugmaker Alexion Pharmaceuticals fared better in its revenue and adjusted earnings figures in the…

Germany’s science and technology company Merck KGaA today announced its investment in SynSense (formerly…

Eye health specialist Bausch + Lomb, part Bausch Health Companies, has entered into an exclusive licensing…